Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004800213 | Breast | IDC | antigen processing and presentation of peptide antigen | 18/1434 | 62/18723 | 5.28e-07 | 2.59e-05 | 18 |
GO:000247813 | Breast | IDC | antigen processing and presentation of exogenous peptide antigen | 13/1434 | 38/18723 | 2.60e-06 | 1.01e-04 | 13 |
GO:000248314 | Breast | IDC | antigen processing and presentation of endogenous peptide antigen | 9/1434 | 19/18723 | 4.03e-06 | 1.43e-04 | 9 |
GO:001988313 | Breast | IDC | antigen processing and presentation of endogenous antigen | 10/1434 | 26/18723 | 1.14e-05 | 3.08e-04 | 10 |
GO:001988413 | Breast | IDC | antigen processing and presentation of exogenous antigen | 13/1434 | 47/18723 | 3.53e-05 | 8.08e-04 | 13 |
GO:00198829 | Breast | IDC | antigen processing and presentation | 20/1434 | 106/18723 | 1.41e-04 | 2.49e-03 | 20 |
GO:001988513 | Breast | IDC | antigen processing and presentation of endogenous peptide antigen via MHC class I | 7/1434 | 17/18723 | 1.49e-04 | 2.61e-03 | 7 |
GO:000247412 | Breast | IDC | antigen processing and presentation of peptide antigen via MHC class I | 8/1434 | 28/18723 | 9.00e-04 | 1.04e-02 | 8 |
GO:001583312 | Breast | IDC | peptide transport | 32/1434 | 264/18723 | 6.61e-03 | 4.62e-02 | 32 |
GO:004800222 | Breast | DCIS | antigen processing and presentation of peptide antigen | 20/1390 | 62/18723 | 1.01e-08 | 7.56e-07 | 20 |
GO:000247822 | Breast | DCIS | antigen processing and presentation of exogenous peptide antigen | 15/1390 | 38/18723 | 3.22e-08 | 2.09e-06 | 15 |
GO:001988422 | Breast | DCIS | antigen processing and presentation of exogenous antigen | 15/1390 | 47/18723 | 8.26e-07 | 3.39e-05 | 15 |
GO:000248323 | Breast | DCIS | antigen processing and presentation of endogenous peptide antigen | 9/1390 | 19/18723 | 3.11e-06 | 1.02e-04 | 9 |
GO:001988323 | Breast | DCIS | antigen processing and presentation of endogenous antigen | 10/1390 | 26/18723 | 8.68e-06 | 2.37e-04 | 10 |
GO:001988214 | Breast | DCIS | antigen processing and presentation | 22/1390 | 106/18723 | 8.76e-06 | 2.38e-04 | 22 |
GO:001988523 | Breast | DCIS | antigen processing and presentation of endogenous peptide antigen via MHC class I | 7/1390 | 17/18723 | 1.23e-04 | 2.12e-03 | 7 |
GO:000247422 | Breast | DCIS | antigen processing and presentation of peptide antigen via MHC class I | 9/1390 | 28/18723 | 1.26e-04 | 2.18e-03 | 9 |
GO:000247810 | Cervix | CC | antigen processing and presentation of exogenous peptide antigen | 18/2311 | 38/18723 | 1.20e-07 | 6.06e-06 | 18 |
GO:004800210 | Cervix | CC | antigen processing and presentation of peptide antigen | 24/2311 | 62/18723 | 1.21e-07 | 6.07e-06 | 24 |
GO:001988410 | Cervix | CC | antigen processing and presentation of exogenous antigen | 20/2311 | 47/18723 | 2.18e-07 | 9.57e-06 | 20 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516328 | Oral cavity | OSCC | Human cytomegalovirus infection | 139/3704 | 225/8465 | 2.77e-08 | 2.38e-07 | 1.21e-07 | 139 |
hsa0414528 | Oral cavity | OSCC | Phagosome | 88/3704 | 152/8465 | 2.83e-04 | 9.13e-04 | 4.65e-04 | 88 |
hsa0461229 | Oral cavity | OSCC | Antigen processing and presentation | 47/3704 | 78/8465 | 2.37e-03 | 6.35e-03 | 3.23e-03 | 47 |
hsa05169113 | Oral cavity | OSCC | Epstein-Barr virus infection | 144/3704 | 202/8465 | 1.08e-15 | 3.60e-14 | 1.83e-14 | 144 |
hsa05170111 | Oral cavity | OSCC | Human immunodeficiency virus 1 infection | 133/3704 | 212/8465 | 1.42e-08 | 1.40e-07 | 7.12e-08 | 133 |
hsa05163112 | Oral cavity | OSCC | Human cytomegalovirus infection | 139/3704 | 225/8465 | 2.77e-08 | 2.38e-07 | 1.21e-07 | 139 |
hsa04145113 | Oral cavity | OSCC | Phagosome | 88/3704 | 152/8465 | 2.83e-04 | 9.13e-04 | 4.65e-04 | 88 |
hsa04612113 | Oral cavity | OSCC | Antigen processing and presentation | 47/3704 | 78/8465 | 2.37e-03 | 6.35e-03 | 3.23e-03 | 47 |
hsa0516929 | Oral cavity | LP | Epstein-Barr virus infection | 106/2418 | 202/8465 | 4.30e-13 | 9.54e-12 | 6.15e-12 | 106 |
hsa0414529 | Oral cavity | LP | Phagosome | 73/2418 | 152/8465 | 2.37e-07 | 3.29e-06 | 2.12e-06 | 73 |
hsa0517028 | Oral cavity | LP | Human immunodeficiency virus 1 infection | 92/2418 | 212/8465 | 2.18e-06 | 2.20e-05 | 1.42e-05 | 92 |
hsa04612210 | Oral cavity | LP | Antigen processing and presentation | 37/2418 | 78/8465 | 2.98e-04 | 1.60e-03 | 1.03e-03 | 37 |
hsa0516329 | Oral cavity | LP | Human cytomegalovirus infection | 85/2418 | 225/8465 | 1.55e-03 | 6.89e-03 | 4.45e-03 | 85 |
hsa0516936 | Oral cavity | LP | Epstein-Barr virus infection | 106/2418 | 202/8465 | 4.30e-13 | 9.54e-12 | 6.15e-12 | 106 |
hsa0414536 | Oral cavity | LP | Phagosome | 73/2418 | 152/8465 | 2.37e-07 | 3.29e-06 | 2.12e-06 | 73 |
hsa0517037 | Oral cavity | LP | Human immunodeficiency virus 1 infection | 92/2418 | 212/8465 | 2.18e-06 | 2.20e-05 | 1.42e-05 | 92 |
hsa0461237 | Oral cavity | LP | Antigen processing and presentation | 37/2418 | 78/8465 | 2.98e-04 | 1.60e-03 | 1.03e-03 | 37 |
hsa0516337 | Oral cavity | LP | Human cytomegalovirus infection | 85/2418 | 225/8465 | 1.55e-03 | 6.89e-03 | 4.45e-03 | 85 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TAP1 | SNV | Missense_Mutation | novel | c.516G>C | p.Leu172Phe | p.L172F | Q03518 | protein_coding | tolerated(0.05) | benign(0.261) | TCGA-A2-A0D4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
TAP1 | SNV | Missense_Mutation | novel | c.1356A>C | p.Glu452Asp | p.E452D | Q03518 | protein_coding | tolerated(0.21) | benign(0.038) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TAP1 | SNV | Missense_Mutation | | c.1601N>A | p.Ser534Tyr | p.S534Y | Q03518 | protein_coding | deleterious(0) | possibly_damaging(0.578) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
TAP1 | insertion | Nonsense_Mutation | novel | c.591_592insCTCCTCTCTTGGTAAGGGGAACGCAGGGCAAGAGGGGAGGAC | p.Pro197_Thr198insLeuLeuSerTrpTerGlyGluArgArgAlaArgGlyGluAsp | p.P197_T198insLLSW*GERRARGED | Q03518 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TAP1 | SNV | Missense_Mutation | rs550037204 | c.809G>A | p.Arg270His | p.R270H | Q03518 | protein_coding | tolerated(0.07) | benign(0.115) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TAP1 | SNV | Missense_Mutation | rs777683307 | c.1336N>A | p.Glu446Lys | p.E446K | Q03518 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
TAP1 | SNV | Missense_Mutation | | c.2200G>A | p.Asp734Asn | p.D734N | Q03518 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TAP1 | SNV | Missense_Mutation | | c.1099C>A | p.Leu367Met | p.L367M | Q03518 | protein_coding | tolerated(0.56) | benign(0.225) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TAP1 | SNV | Missense_Mutation | | c.473N>A | p.Pro158Gln | p.P158Q | Q03518 | protein_coding | deleterious(0.02) | possibly_damaging(0.823) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TAP1 | SNV | Missense_Mutation | | c.1115G>A | p.Arg372Gln | p.R372Q | Q03518 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |